A Pilot Study of a Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma
Latest Information Update: 11 May 2023
At a glance
- Drugs Poly ICLC (Primary) ; Retifanlimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 05 May 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Feb 2023 Planned End Date changed from 1 Jan 2028 to 1 Apr 2028.
- 08 Feb 2023 Planned primary completion date changed from 1 Jan 2027 to 1 Apr 2027.